Cyclic nucleotides and phosphodiesterases in platelets

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 412-423

  Haslam, Richard J ^a   Dickinson, Natalie T ^a   Jang, Elliott K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; LIXAZINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; THROMBOCYTE ENZYME; ZAPRINAST;

CELL LYSATE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN FAMILY;

EID: 0032725027     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615861     Document Type: Conference Paper

References (88)

1. Haslam RJ, Davidson MML, Davies T, Lynham JA, McClenaghan MD. Regulation of blood platelet function by cyclic nucleotides. In: Advances in Cyclic Nucleotide Research, vol. 9. George WJ, Ignarro LJ, eds. New York: Raven Press 1978; 533-552.
2. Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev. 1995;9:143-156.
3. Schmidt HHHW, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta. 1993;1178:153-175.
4. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
5. Thompson WJ. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther. 1991;51:13-33.
6. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
7. Perry MJ, Higgs GA. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol. 1998;2:472-481.
8. Simpson AWM, Reeves ML, Rink TJ. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol. 1988;37:2315-2320.
9. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol. 1986;35:787-800.
10. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H, Nakano T. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signalling. 1996;8:575-581.
11. Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem. 1982;257:1973-1979.
12. Stroop SD, Beavo JA. Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem. 1991;266:23802-23809.
13. MacFarland RT, Zelus BD, Beavo JA. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem. 1991;266:136-142.
14. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem. 1993;268:26286-26295.
15. Yang Q, Paskind M, Bolger G, Thompson WJ, Repaske DR, Cutler LS, Epstein PM. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun. 1994;205:1850-1858.
16. Podzuweit T, Nennstiel P, Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl)adenine. Cell Signaling 1995; 7:733-738.
17. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 1997;272:6823-6826.
18. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990;37:671-681.
19. Maurice DH, Haslam RJ. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol. 1990;191:471-475.
20. Meacci E, Taira M, Moos M, Smith CJ, Movsesian MA, Degerman E, Belfrage P, Manganiello V. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 1992;89:3721-3725.
21. Liu H, Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol. 1998;125:1501-1510.
22. Kasuya J, Goko H, Fujita-Yamaguchi Y. Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J Biol Chem. 1995;270:14305-14312.
23. Meanwell NA. Inhibitors of platelet phosphodiesterase: Potential antithrombotic agents. Drug News Perspect. 1991;4:400-413.
24. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, Saitoh Y. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther. 1979;211:26-30.
25. Ochiai M, Isshiki T, Takeshita S, Eto K, Toyoizumi H, Sato T, Miyashita H. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am J Cardiol. 1997;79:1471-1474.
26. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation. 1998;98:678-686.
27. Fischer TA, Erbel R, Treese N. Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs. 1992;44:928-945.
28. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. for the PROMISE Study Research Group. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
29. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Eng J Med. 1993;329:149-155.
30. Alvarez R, Banerjee GL, Bruno JJ, Jones GL, Liittschwager K, Strosberg AM, Venuti MC. A potent and selective inhibitor of cyclic inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol Pharmacol. 1986;29:554-560.
31. Thomas MK, Francis SH, Corbin JD. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem. 1990;265;14964-14970.
32. Burns F, Rodger IW, Pyne NJ. The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung. Biochem J. 1992;283:487-491.
33. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene. 1998;216:139-147.
34. Turko IV, Francis SH, Corbin JD. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J. 1998;329:505-510.
35. Lochhead A, Nekrasova E, Arshavsky VY, Pyne NJ. The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to y subunit of the photoreceptor cGMP phosphodiesterase. J Biol Chem. 1997;272:18397-18403.
36. Han P, Zhu X, Michaeli T. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem. 1997;272:16152-16157.
37. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA. 1998;95:8991-8996.
38. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 1998;273:15553-15558.
39. Fisher DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:15559-15564.
40. m phosphodiesterase. Biochim Biophys Acta. 1976;429:485-497.
41. Hagiwara M, Endo T, Kanayama T, Hidaka H. Effect of l-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. J Pharmacol Exp Ther. 1984;228:467-471.
42. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J. 1997;323:371-377.
43. Grant PG, Colman RW. Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry. 1984;23:1801-1807.
44. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A a receptor for new cardiotonic drugs. Mol Pharmacol. 1986;29:506-514.
45. m cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci USA. 1986;83:6660-6663.
46. Degerman E, Moos M, Rascón A, Vasta V, Meacci E, Smith CJ, Lindgren S, Andersson K-E, Belfrage P, Manganiello V. Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim Biophys Acta. 1994;1205:189-198.
47. Leroy M-J, Degerman E, Taira M, Murata T, Wang LH, Movsesian MA, Meacci E, Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry. 1996;35:10194-10202.
48. Cheung PP, Xu H, McLaughlin MM, Ghazaleh FA, Livi GP, Colman RW. Human platelet cGI-PDE: Expression in yeast and localization of the catalytic domain by deletion mutagenesis. Blood. 1996;88:1321-1329.
49. Tang KM, Jang EK, Haslam RJ. Expression and mutagenesis of the catalytic domain cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets. Biochem J. 1997;323:217-224.
50. Pillai R, Staub SF, Colicelli J. Mutational mapping of kinetic and pharmacological properties of a human cardiac cAMP phosphodiesterase. J Biol Chem. 1994;269:30676-30681.
51. Masuoka H, Ito M, Sugioka M, Kozeki H, Konishi T, Tanaka T, Nakano T. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochem Biophys Res Commun. 1993;190:412-417.
52. Omburo GA, Brickus T, Ghazaleh FA, Colman RW. Divalent metal cation requirement and possible classification of cGMP-inhibited phosphodiesterase as a metallohydrolase. Arch Biochem Biophys. 1995;323;1-5.
53. Ghazaleh FA, Omburo GA, Cohnan RW. Evidence for the presence of essential histidine and cysteine residues in platelet cGMP-inhibited phosphodiesterase. Biochem J. 1996;317:495-501.
54. Cheung PP, Yu L, Zhang H, Colman RW. Partial characterization of the active site of human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis. Arch Biochem Biophys. 1998;360:99-104.
55. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: Topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol. 1995;47:340-347.
56. Erhardt PW, Hagedorn AA, Sabio M. Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor. Mol Pharmacol. 1988;33:1-13.
57. Venuti MC, Stephenson RA, Alvarez R, Bruno JJ, Strosberg AM. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline. J Med Chem. 1988;31:2136-2145.
58. Macphee CH, Reifsnyder DH, Moore TA, Lerea KM, Beavo JA. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J Biol Chem. 1988;263:10353-10358.
59. m cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci USA. 1988;85:9071-9075.
60. Sheth SB, Brennan KJ, Biradavolu R, Colman RW. Isolation and regulation of the cGMP-inhibited cAMP phosphodiesterase in human erythroleukemia cells. Thromb Haemost. 1997;77:155-162.
61. López-Aparicio P, Rascón A, Manganiello VC, Andersson K-E, Belfrage P, Degerman E. Insulin induced phosphorylation and activation of the cGMP-inhibited cAMP phosphodiesterase in human platelets. Biochem Biophys Res Commun. 1992;186:517-523.
62. Wijkander J, Landström TR, Manganiello V, Belfrage P, Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: Possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology. 1998;139:219-227.
63. Grant PG, Mannarino AF, Colman RW. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets. Thromb Res. 1990;59:105-119.
64. Michie AM, Lobban M, Müller T, Harnett MM, Houslay MD. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signalling. 1996;8:97-110.
65. Méry P-F, Pavoine C, Pecker F, Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol. 1995;48:121-130.
66. Yamamoto T, Yamamoto S, Osborne JC, Manganiello VC, Vaughan M, Hidaka H. Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase. J Biol Chem. 1983;258:14173-14177.
67. Coquil J-F, Franks DJ, Wells JN, Dupuis M, Hamet P. Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets. Biochim Biophys Acta. 1980;631:148-165.
68. Francis SH, Lincoln TM, Corbin JD. Characterization of a novel cGMP binding protein from rat lung. J Biol Chem. 1980;255;620-626.
69. Robichon A. A new cGMP phosphodiesterase isolated from bovine platelets is substrate for cAMP- and cGMP-dependent protein kinases: evidence for a key role in the process of platelet activation. J Cell Biochem. 1991;47:147-157.
70. 1. J Cardiovasc Pharmacol. 1991;17:424-433.
71. Levin RI, Weksler BB, Jaffe EA. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostracyclin synergistically inhibit platelet function. Circulation. 1982;66:1299-1307.
72. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
73. Andersson TLG, Vinge E. Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggregation and cyclic nucleotide levels in human platelets. J Cardiovasc Pharmacol. 1991;18:237-242.
74. Anfossi G, Massucco P, Piretto V, Mularoni E, Cavalot F, Mattiello L, Trovati M. Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: A mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Clin Exp Pharmacol Physiol. 1995;22:803-811.
75. Grünberg B, Negrescu E, Siess W. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost. Eur J Pharmacol. 1995;288:329-333.
76. Fisch A, Michael-Hepp J, Meyer J, Darius H. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol. 1995;289:455-461.
77. Jiang H, Shabb JB, Corbin JD. Cross-activation: overriding cAMP/cGMP selectivities of protein kinases in tissues. Biochem Cell Biol. 1992;70:1283-1289.
78. Jiang H, Colbran JL, Francis SH, Corbin JD. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem. 1992;267:1015-1019.
79. Landgraf W, Hullin R, Göbel C, Hofmann F. Phosphorylation of cGMP-dependent protein kinase increases the affinity for cyclic AMP. Eur J Biochem. 1986;154:113-117.
80. Smith JA, Francis SH, Walsh KA, Kumar S, Corbin JD. Autophosphorylation of Type Iβ cGMP-dependent protein kinase increases basal catalytic activity and enhances allosteric activation by cGMP or cAMP. J Biol Chem. 1996;271:20756-20762.
81. Geiger J, Nolte C, Butt E, Sage SO, Walter U. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci USA. 1992;89:1031-1035.
82. Butt E, Nolle C, Schulz S, Beltman J, Beavo JA, Jastorff B, Walter U. Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-parachlorophenylthio-cGMP. Biochem Pharmacol. 1992;43:2591-2600.
83. Butt E, Pöhler D, Genieser H-G, Huggins JP, Bucher B. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-S-bromo-PET-cyclic GMPS. Br J. Pharmacol. 1995;116:3110-3116.
84. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang G-X, Korth M, Aszódi A, Andersson K-E, Krombach F, Mayerhofer A, Ruth P, Fässler R, Hofmann F. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998;17:3045-3051.
85. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fässler R, Ruth P, Krombach F, Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′, 5′-mon-phosphate kinase I. J Exp Med. 1999; 189:1255-1263.
86. Tang KM, Sherwood JL, Haslam RJ. Photoaffinity labelling of cyclic GMP-binding proteins in human platelets. Biochem J. 1993;294:329-333.
87. Surks HK, Sun B, Zhu Y, Baur W, Hartwig J, Mendelsohn ME. Identification and cloning of a cGMP-gated ion channel from human platelets and megakaryocytes. Circulation. 1995;92:1-36 (Abstr).
88. de Rooij J, Zwartkruis FJT, Verheijen MHG, Cool RH, Nijman SMB, Wittinghofer A, Bos JL. Epac is a Rapl guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396:474-477.